The bidding window for Chemkart India SME IPO was open from July 7, 2025, to July 9, 2025. The basis of allotment will be finalised today, July 10, 2025. Here’s how you can check the IPO allotment status.
Chemkart India IPO is a book-building issue of ₹80.08 crores, consisting a fresh issue of ₹64.48 crores and OFS (Offer For Sale) of ₹15.60 crores. The price band is set at ₹236 to ₹248 per share. The tentative listing on BSE is July 14, 2025.
Smart Horizon Capital Advisors Private Limited is the book-running lead manager, and Bigshare Services Pvt Ltd is the registrar for the issue.
The net proceeds from the fresh issue will be used towards:
(July 9, 2025, end of the day)
Category |
Subscription (times) |
Qualified Institutional Investors (QIBs) |
13.69 |
Non-Institutional Investors |
5.64 |
Retail Individual Investors(RIIs) |
1.63 |
Total |
5.91 |
As of 10 July 2025, Chemkart India IPO GMP stood at nil. The shares are expected to list at par with the issue price of ₹248.
Source: Business Standard Report dated 10 July, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Chemkart India Limited operates as a supplier of nutritional, health, and sports supplement products, primarily emphasizing food-based items that offer both nutritional value and health-enhancing benefits. Their product portfolio consists of seven main categories: Amino Acids, Health Supplements, Herbal Extracts, Nucleotides, Proteins, Sports Nutrition, and Vitamins.
For the financial year 2025, Chemkart India Limited reported revenues of ₹20,327.85 Lakhs, compared to ₹13,202.69 Lakhs in FY 2024 and ₹13,137.78 Lakhs in FY 2023.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here